RS20060194A - Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases - Google Patents

Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases

Info

Publication number
RS20060194A
RS20060194A YUP-2006/0194A YUP20060194A RS20060194A RS 20060194 A RS20060194 A RS 20060194A YU P20060194 A YUP20060194 A YU P20060194A RS 20060194 A RS20060194 A RS 20060194A
Authority
RS
Serbia
Prior art keywords
diseases
metalloproteinases
matrix
disease
articulation
Prior art date
Application number
YUP-2006/0194A
Other languages
English (en)
Inventor
Hans Matter
Armin Hofmeister
Manfred Schudok
Original Assignee
Aventis Pharma Deutschland Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh., filed Critical Aventis Pharma Deutschland Gmbh.,
Publication of RS20060194A publication Critical patent/RS20060194A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Jedinjenja formule I su pogodna za proizvodnju lekova za profilaksu i lečenje svih onih obolenja, u čijem toku sudeluje pojačana aktivnost matrix-metaloproteinaza. Tu spadaju oboljenja kao što su degenerativna obolenja zglobova kao naprimer osteoartroze, spondiloze, atrofija hrskavice posle traume zgloba ili dužeg mirovanja zgloba posle povrede meniskusa ili povrede čašice u kolenu ili prekida veza (ligamenata) ili obolenja vezivnog tkiva kao što su kolagenaze, periodontalna obolenja, smetnje pri zaceljenju rana i hronična obolenja sistema za kretanje kao što su zapaljenski, imunološki ili metabolički uslovljena akutna i hronična zapaljenja zglobova, artropatije, mialgije i oštećenja metabolizma kostiju ili ulceracije, ateroskleroze i stenoze ili za bolesti zapaljenja ili bolesti raka, nastajanja metastaze tumora, kaheksije, anoreksije ili septičnih šokova.
YUP-2006/0194A 2003-09-27 2004-09-14 Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases RS20060194A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10344936A DE10344936A1 (de) 2003-09-27 2003-09-27 Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
PCT/EP2004/010248 WO2005030728A1 (de) 2003-09-27 2004-09-14 Bicyclische iminosäurederivate als inhibitoren von matrix-metalloproteinasen

Publications (1)

Publication Number Publication Date
RS20060194A true RS20060194A (en) 2008-08-07

Family

ID=34353126

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2006/0194A RS20060194A (en) 2003-09-27 2004-09-14 Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases

Country Status (24)

Country Link
EP (1) EP1670766B1 (sr)
JP (1) JP4861179B2 (sr)
KR (1) KR20060086367A (sr)
CN (1) CN1856478B (sr)
AR (1) AR046165A1 (sr)
AT (1) ATE550327T1 (sr)
AU (1) AU2004275937A1 (sr)
BR (1) BRPI0414594A (sr)
CA (1) CA2539731A1 (sr)
DE (1) DE10344936A1 (sr)
IL (1) IL174040A0 (sr)
MA (1) MA28075A1 (sr)
ME (1) MEP33008A (sr)
MX (1) MXPA06002927A (sr)
MY (1) MY139830A (sr)
NO (1) NO20061837L (sr)
NZ (1) NZ546158A (sr)
PE (1) PE20050432A1 (sr)
RS (1) RS20060194A (sr)
RU (1) RU2335494C2 (sr)
TW (1) TW200520755A (sr)
UY (1) UY28539A1 (sr)
WO (1) WO2005030728A1 (sr)
ZA (1) ZA200601501B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
ES2658964T3 (es) 2007-08-03 2018-03-13 Nucitec S.A. De C.V. Composiciones y métodos para el tratamiento y la prevención de la osteoartritis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (sr) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
CN1131215C (zh) * 1995-11-13 2003-12-17 赫彻斯特股份公司 环和杂环N－取代的α－亚氨基异羟肟酸和羧酸
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
DE69807845T2 (de) * 1997-01-23 2003-06-05 Hoffmann La Roche Sulfamide-metalloprotease inhibitoren
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
MXPA06002927A (es) 2006-06-14
CN1856478A (zh) 2006-11-01
NO20061837L (no) 2006-06-01
BRPI0414594A (pt) 2006-11-07
PE20050432A1 (es) 2005-07-21
CA2539731A1 (en) 2005-04-07
AU2004275937A1 (en) 2005-04-07
KR20060086367A (ko) 2006-07-31
JP4861179B2 (ja) 2012-01-25
IL174040A0 (en) 2006-08-01
NZ546158A (en) 2008-11-28
JP2007506690A (ja) 2007-03-22
AR046165A1 (es) 2005-11-30
WO2005030728A1 (de) 2005-04-07
MA28075A1 (fr) 2006-08-01
UY28539A1 (es) 2005-04-29
CN1856478B (zh) 2010-05-26
TW200520755A (en) 2005-07-01
ATE550327T1 (de) 2012-04-15
RU2006114352A (ru) 2006-08-27
EP1670766B1 (de) 2012-03-21
MY139830A (en) 2009-10-30
RU2335494C2 (ru) 2008-10-10
DE10344936A1 (de) 2005-04-21
MEP33008A (en) 2010-10-10
EP1670766A1 (de) 2006-06-21
ZA200601501B (en) 2007-04-25

Similar Documents

Publication Publication Date Title
WO2005073236A3 (de) Thieno-iminosäure-derivate als inhibitoren von matrix-metalloproteinasen
ATE349435T1 (de) Dpiv-inhibitoren auf glutaminbasis
RS20050363A (en) Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
MA33909B1 (fr) Pyrrolidinones accoles en tant d'inhibiteurs de syk
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
SE0303180D0 (sv) Novel compounds
GB0121033D0 (en) Organic compounds
SE0302232D0 (sv) Novel Compounds
ATE331718T1 (de) Spirosubstituierte pyrrolopyrimidine
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
AU2003209118A1 (en) Aryl ureas as kinase inhibitors
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
MX2010009658A (es) Derivados de azetidina.
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
WO2005097762A3 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20061837L (no) Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser
MXPA05010020A (es) Derivados de oxamida.
DE69702182T2 (de) Alkylierte styrole als prodrugs zu cox-2-inhibitoren
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
BRPI0606493A2 (pt) derivados de tetrahidrofurano para uso como inibidores das metaloproteinases da matriz
BR0308088A (pt) ácidos alfa-iminocarboxìlicos substituìdos com n, cìclicos, para a inibição seletiva de colagenase